While it may be appropriate to continue G-only mobilization for some MM patients, current guidance should adapt to allow for cyclo-G priming in situations where the risk of additional chemotherapy exposure is deemed to be outweighed by a more optimal PBSC mobilization strategy, even in a post-pandemic environment. With hematology patients being particularly vulnerable to COVID-19 infection, the National Institute of Health and Care Excellence (NICE) issued rapid guidance advising G-CSF only (G-only) priming for PBSC mobilization [[4]]. Despite the dramatic improvement in multiple myeloma (MM) treatment, high-dose therapy and autologous stem cell transplantation (ASCT) continues to offer superior progression free and overall survival in transplant-eligible, newly diagnosed MM (NDMM) [[1]]. Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone. [Extracted from the article]